Want to see IN:TAKE full AI Analyst Report?
Top Page
TAKE Solutions Limited
(TAKE)
Select Model
Select Model
Rating:42Neutral
Price Target:
₹19.50
▼(-51.88% Downside)
Action:Upgraded
Date:07/17/26
The score is weighed down primarily by weak and volatile financial performance—especially negative operating cash flow in consecutive years despite reported net income and weak core profitability in FY2026. Technicals also detract due to a strong downtrend (price below all key moving averages and negative MACD), even though momentum indicators are oversold. Valuation is only modestly supportive, with a P/E around 27 and no dividend yield data to offset fundamental and trend risks.
Positive Factors
Zero net debt
Reported zero total debt in FY2025–FY2026 materially reduces financial leverage and interest burden, improving capital flexibility. Over a 2–6 month horizon this stronger liability position lowers default risk and gives management room to invest in product or absorb shocks without external financing.
Negative Factors
Negative operating cash flow
Consecutive years of negative operating cash flow despite reported net income signal weak earnings cash conversion and structural working capital or collection issues. Persistent cash burn constrains reinvestment, increases reliance on non‑operating items, and undermines long‑term financial resilience.
Read all positive and negative factors
Positive Factors
Negative Factors
Zero net debt
Reported zero total debt in FY2025–FY2026 materially reduces financial leverage and interest burden, improving capital flexibility. Over a 2–6 month horizon this stronger liability position lowers default risk and gives management room to invest in product or absorb shocks without external financing.
Read all positive factors
TAKE Solutions Limited (TAKE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹2.83B
Dividend YieldN/A
Average Volume (3M)58.94K
Price to Earnings (P/E)25.9
Beta (1Y)1.36
Revenue GrowthN/A
EPS Growth-71.36%
CountryIN
Employees203
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)0.74
Shares Outstanding147,934,000
10 Day Avg. Volume129,011
30 Day Avg. Volume58,943
Financial Highlights & Ratios
PEG Ratio-0.75
Price to Book (P/B)18.74
Price to Sales (P/S)10.72
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
TAKE Solutions Limited Business Overview & Revenue Model
Company Description
TAKE Solutions Limited, operating across the United States, Asia Pacific, and Europe, specializes in providing expert services and cutting-edge solutions for the life sciences and supply chain management sectors. For the life sciences industry, th...
How the Company Makes Money
null...
TAKE Solutions Limited Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
46
Neutral
Cash Flow
29
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 541.85M | 0.00 | 656.08M | 1.89B | 6.53B |
| Gross Profit | -4.44M | -450.00K | 411.67M | 1.06B | 4.60B |
| EBITDA | -19.14M | 27.44M | -1.05B | -209.79M | 269.00M |
| Net Income | 108.49M | 374.67M | -1.20B | -1.00B | -7.82B |
Balance Sheet | |||||
| Total Assets | 362.41M | 364.79M | 881.05M | 2.24B | 12.23B |
| Cash, Cash Equivalents and Short-Term Investments | 186.41M | 156.91M | 8.49M | 113.36M | 290.71M |
| Total Debt | 0.00 | 0.00 | 370.85M | 463.69M | 779.90M |
| Total Liabilities | 52.40M | 159.52M | 969.78M | 1.16B | 10.42B |
| Stockholders Equity | 310.01M | 205.27M | -88.73M | 1.09B | 1.81B |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -163.66M | 14.00M | -123.81M | 890.99M |
| Operating Cash Flow | -27.76M | -163.66M | 93.16M | 200.15M | 1.20B |
| Investing Cash Flow | 1.00K | 220.20M | -74.62M | -21.25M | -306.41M |
| Financing Cash Flow | -3.75M | -32.39M | -117.35M | -357.21M | -545.17M |
TAKE Solutions Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | ₹140.14B | 54.01 | ― | 0.80% | -12.10% | -29.80% | |
59 Neutral | ₹30.00B | 30.83 | ― | ― | 8.13% | 2910.16% | |
56 Neutral | ₹707.65B | 156.70 | ― | 0.12% | 10.91% | -67.33% | |
56 Neutral | ₹168.49B | 52.98 | ― | 0.19% | 2.64% | -36.18% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | ₹189.22B | -256.71 | ― | ― | 47.33% | 57.44% | |
42 Neutral | ₹2.83B | 25.89 | ― | ― | ― | -71.36% |
* General Sector Average
IN:TAKE
TAKE Solutions Limited
19.15
8.93
87.38%
IN:BIOCON
Biocon Limited
437.00
42.97
10.91%
IN:CONCORDBIO
Concord Biotech Ltd.
1,339.60
-563.48
-29.61%
IN:DCAL
Dishman Carbogen Amcis Ltd.
191.35
-67.05
-25.95%
IN:SYNGENE
Syngene International Ltd.
417.40
-252.35
-37.68%
IN:ONESOURCE
OneSource Specialty Pharma Limited
1,650.45
-349.85
-17.49%
TAKE Solutions Limited Corporate Events
TAKE Limited Launches Postal Ballot to Approve Special Business Resolution
Jul 13, 2026
TAKE Limited has initiated a postal ballot process to seek shareholder approval for special business items through remote e-voting and physical ballot forms. The exercise is being conducted under the Companies Act, SEBI listing regulations, and re...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.